Phase II study of oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma. - Université de Lille Accéder directement au contenu
Article Dans Une Revue Haematologica Année : 2018

Phase II study of oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma.

Marc Andre
  • Fonction : Auteur
Oumedaly Reman
  • Fonction : Auteur
Olivier Casasnovas
  • Fonction : Auteur

Résumé

JAK2 constitutive activation/overexpression is common in classical Hodgkin lymphoma, and several cytokines stimulate Hodgkin lymphoma cells by recognizing JAK1-/JAK2-bound receptors. JAK blockade may thus be therapeutically beneficial in Hodgkin lymphoma. In this phase II study we assessed the safety and efficacy of ruxolitinib, an oral JAK1/2 inhibitor, in patients with relapsed/refractory Hodgkin lymphoma. The primary objective was overall response rate according to the International Harmonization Project 2007 criteria. Thirty-three patients with advanced disease (median number of prior lines of treatment: 5; refractory: 82%) were included; nine (27.3%) received at least six cycles of ruxolitinib and six (18.2%) received more than six cycles. The overall response rate after six cycles was 9.4% (3/32 patients). All three responders had partial responses; another 11 patients had transient stable disease. Best overall response rate was 18.8% (6/32 patients). Rapid alleviation of B-symptoms was common. The median duration of response was 7.7 months, median progression-free survival 3.5 months (95% CI: 1.9-4.6), and the median overall survival 27.1 months (95% CI: 14.4-27.1). Forty adverse events were reported in 14/33 patients (42.4%). One event led to treatment discontinuation, while 87.5% of patients recovered without sequelae. Twenty-five adverse events were grade 3 or higher. These events were mostly anemia (n=11), all considered related to ruxolitinib. Other main causes of grade 3 or higher adverse events included lymphopenia and infections. Of note, no cases of grade 4 neutropenia or thrombocytopenia were observed. Ruxolitinib shows signs of activity, albeit short-lived, beyond a simple anti-inflammatory effect. Its limited toxicity suggests that it has the potential to be combined with other therapeutic modalities. ClinicalTrials.gov: NCT01877005.
Fichier principal
Vignette du fichier
8454-Article Text-58765-1-10-20200724.pdf (768.13 Ko) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-03169704 , version 1 (15-03-2021)

Licence

Paternité - Pas d'utilisation commerciale

Identifiants

Citer

Eric van den Neste, Marc Andre, Thomas Gastinne, Aspasia Stamatoullas-Bastard, Corinne Haioun, et al.. Phase II study of oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma.. Haematologica, 2018, 108 (5), pp.840-847. ⟨10.3324/haematol.2017.180554⟩. ⟨hal-03169704⟩
61 Consultations
53 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More